Therapeutic targeting autophagy to sensitize cancer immunotherapy in prostate cancer

Yuanyuan Qiao1,2,3, Jae E. Choi4,5, Josh N. Vo1,5, Jean C. Tien1,2,3, Lisha Wang1, Lanbo Xiao1, Stephanie A. Simko1, Andrew D. Delekta1, Nathan B. Hodge1, Parth Desai1, Kristin Juckette1, Alice Xu1, Fengyun Su1, Rui Wang1, Xuhong Cao1,5, Xiaoju Wang1, Xiaoming Wang1,2, Javed Siddiqui1, Zhen Wang7, Amélie Bernard8,9, Ester Fernandez-Salas1, Nora M. Navone10, Ke Ding1, Eeva-Liisa Eskelinen11, Elisabeth I. Heath12, Daniel J. Klionsky14, Weiping Zou2,3,13, and Arul M. Chinnaiyan1,2,3,6,14

1Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan 48109, USA.
2Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109, USA.
3Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, USA.
4School of Medicine, University of California, San Diego, California 92093, USA.
5Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan 48109, USA.
6Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan 48109, USA.
7School of Pharmacy, Jinan University, Guangzhou 510632, China.
8CNRS, Laboratoire de Biogenèse Membranaire, UMR5200; Université de Bordeaux, Laboratoire de Biogenèse Membranaire, UMR5200, 33000 Bordeaux, France.
9Life Sciences Institute and Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, Michigan 48109, USA.
10Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
11Institute of Biomedicine, University of Turku, 20520 Turku, Finland.
12Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
13Department of Surgery, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA.
14Department of Urology, University of Michigan, Ann Arbor, Michigan 48109, USA.

Although cancer immunotherapy has revolutionized cancer treatment, patient response to immunotherapy remains varied. Despite progress, the mechanisms limiting cancer immunotherapy are not yet fully understood. A low number of tumor infiltrating T cells (cold tumor) is one of the limiting factors for cancer immunotherapy. Agents that enhance immunotherapy by shifting cold tumors to hot tumors will greatly benefit cancer immunotherapy. In prostate cancer, the majority of tumors are known to be cold and hence, cancer immunotherapy is not the ideal treatment option. Here, we use a prostate cancer model as an example to demonstrate that modulating the tumor microenvironment through altering autophagy will change the tumor cytokine secretion profile, which in turn attracts immune lymphocytes into the tumor microenvironment. In tandem, we have identified a candidate compound known as ESK981 for such a purpose. ESK981 is a potent anti-cancer multi-tyrosine kinase inhibitor with novel autophagy-inducing property. As a Phase-I cleared small molecule, ESK981 has been proven to be useful in multiple types of cancer by enhancing immunotherapy.

Method
A small molecule library was used for screening autophagy activity and cytokine secretion. Various types of human cancer cell lines (prostate, renal, bladder, breast etc.) and multiple syngeneic mouse lines were examined for autophagy activity as well as an in vitro response to interferon stimulation with or without ESK981. A syngeneic mouse prostate cancer was used for the in vivo examination of autophagy as well as the anti-tumor effect by ESK981 monotherapy and/or in combination with anti-PD-1 therapy.

Conclusion
We have discovered a robust, novel autophagy-modulating small molecule, named ESK981, for the treatment of various cancer types as a monotherapy. In addition, we have demonstrated that autophagy has an essential role in the anti-tumor effect of immunotherapy, especially for anti-PD-1 in syngeneic
prostate cancer model. Therefore, the use of a small molecule such as ESK981 to target autophagy can enhance immunological infiltration induced by cancer immunotherapy, such as immune checkpoint blockade, for non-immunogenic tumors.

**Conflict of Interest Statement**
A.M.C. is a co-founder and serves on the Scientific Advisory Board of Esanik Therapeutics, Inc. which owns to the rights to the clinical development of ESK981. Esanik Therapeutics, Inc. did not fund or approve the conduct of this study.

**Funding**
This project is supported by Prostate Cancer Foundation.